posted by admin on Dec 30
More info…
Pfizer Inc. announced that the Food and Drug Administration (FDA) issued a Complete Response letter regarding the companys New Drug Application (NDA) for Lyrica (pregabalin) capsules CV as a monotherapy treatment for generalized anxiety disorder (GAD). The FDA determined that the data contained in the NDA were insufficient to support approval.
Money woes are all in your head (USA Today)
Suffering from anxiety, worry or despair about your financial situation? Lacking enough savings? Have too much debt?
Leave a Reply
You must be logged in to post a comment.